Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
News
New Data at ASH 2021 Reinforces the Strength of Servier’s Hematology Portfolio
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma
Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
Servier Announces Promising Phase 1 Data for Vorasidenib in IDH Mutant Low-Grade Glioma Published in Clinical Cancer Research
Servier Presents Updated Translational Data from Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib tablets) in Patients with IDH Mutant Low-Grade Glioma at ASCO 2021
Servier Highlights Novel Approaches to Treating Cancer at the ASCO and EHA 2021 Annual Meetings
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Cholangiocarcinoma
Servier Completes Acquisition of Agios Pharmaceuticals’ Oncology Business